MDA5抗体;MDA5 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of MDA5 expression in THP1 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

MDA5 (melanoma differentiation-associated protein 5), encoded by the *IFIH1* gene, is a cytosolic RNA helicase belonging to the RIG-I-like receptor (RLR) family. It functions as a pattern recognition receptor (PRR) that detects long double-stranded RNA (dsRNA) from viral infections or endogenous sources, triggering innate immune responses via the MAVS/IPS-1 signaling pathway. This activates transcription factors (IRF3/7. NF-κB) to induce type I interferons (IFNs) and proinflammatory cytokines.

Anti-MDA5 autoantibodies are primarily associated with autoimmune conditions, notably dermatomyositis (DM), particularly in clinically amyopathic DM (CADM). These autoantibodies target the MDA5 protein, disrupting its normal antiviral signaling and correlating with distinct clinical features, such as skin ulcers, palmar papules, and rapidly progressive interstitial lung disease (RP-ILD), a life-threatening complication.

First identified in 2005. anti-MDA5 antibodies are detected via immunoprecipitation or ELISA. Their presence is a critical biomarker for diagnosing MDA5-associated DM and stratifying disease severity, especially in Asian populations. RP-ILD linked to anti-MDA5 antibodies has a high mortality rate, necessitating aggressive immunosuppressive therapies (e.g., glucocorticoids, cyclophosphamide, rituximab). Research continues to explore their pathogenic role, including potential interference with viral RNA sensing or induction of proapoptotic pathways. Early detection improves prognosis, highlighting their clinical relevance in autoimmune and inflammatory disorders.